12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Company News  |  Deals

Advinus, Takeda deal

Takeda and Advinus partnered to discover compounds against predefined undisclosed targets for inflammation, CNS and metabolic diseases. Under the three-year deal, Advinus is responsible for discovering optimized IND-ready compounds, while...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >